Metabolic supplement for Alzheimer's disease
Part of Brain & nervous system, Mental health clinical trials.
This trial tests a special supplement combination designed to support brain energy use in people with Alzheimer's. It aims to see if the supplement can help slow cognitive decline.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 50 years old or older and cannot become pregnant.
- You have been diagnosed with Alzheimer's disease with mild to moderate symptoms.
- Your Alzheimer's treatments have been stable for at least one month.
- You are not taking vitamins, omega-3s, or plant sterol supplements for at least one week before starting.
- You have not had a stroke, severe swallowing problems, or uncontrolled diabetes (A1c > 8).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage study tests whether taking glutathione can affect brain “inflammation” and metabolism in people with Alzheimer’s disease. You might benefit from a new treatment approach, while helping researchers understand what works best for early Alzheimer’s-related brain changes.
This study tests whether taking nicotinamide riboside (a form of niacin) affects early memory changes in people with mild cognitive impairment (MCI) or mild Alzheimer’s disease (AD). It also uses passive wearable or sensor data (“digital biomarkers”) to measure changes over time.
This trial tests whether stem cells from donated fat tissue can help people with mild to moderate Alzheimer's disease. It combines infusions of these cells with standard care, and includes brain scans and memory tests to see if the treatment is safe and effective.
This trial tests whether NPC-1, a new drug, can help people with early memory changes or Alzheimer's. Your blood or PET scan will show if you have Alzheimer's-related brain changes, which is required for this study.
This trial tests a new drug called CM383 in people with mild cognitive impairment or mild Alzheimer's disease. The goal is to see if it can help slow down memory loss.
This study looks at how effective a treatment is in people newly diagnosed with mild to moderate Alzheimer’s disease. It also involves health and medication history checks and likely stool (fecal) sample collection to monitor effects.
Hear when a new Alzheimer Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.